Small molecule · Inhibitor of 26S proteasome · developed by Takeda Pharms Usa
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome, the protein complex that degrades ubiquitinated proteins. Blocking this degradation disrupts cell homeostasis and can lead to cancer cell death. It is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 28, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06152575 | Phase 3 | Multiple Myeloma | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Myeloma
Updated Nov 15, 2026.